Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematology
•
Nephrology
•
Glomerulonephritis
Would you consider initiating eculizumab without plasmapheresis as initial therapy for a patient with renal TMA who has a low suspicion of TTP based on a scoring algorithm?
Frimat M, et al., PMID 39342982
Related Questions
How would you treat idiopathic isolated renal TMA diagnosed on renal biopsy without evidence of MAHA?
What would be your approach to managing severe ANCA-associated vasculitis in a patient who is also septic from a bacterial infection?
Under what circumstances would you consider obinutuzumab instead of rituximab when treating primary membranous nephropathy?
Do you modify the albumin level below which you would prophylactically anticoagulate a pregnant patient with nephrotic-range proteinuria, given that hypoalbuminemia is expected in pregnancy?
How do you approach distinguishing between primary and secondary FSGS in a patient who is PLA2R negative?
How do you address patient concerns regarding the necessity of REMS monitoring when prescribing sparsentan?
How do you counsel patients who are found to have a carrier mutation in a single high-risk APOL1 allele?
Would you consider using a combination regimen of rituximab, low-dose cyclophosphamide, and steroids to improve complete remission rates in patient with PLA2R-positive membranous nephropathy?
How does your approach to the differential diagnosis of membranous nephropathy change when PLA2R positivity is detected alongside a chronic viral infection such as HIV, HBV, or HCV?
Which clinical characteristics would prompt you to consider an oral factor B inhibitor such as iptacopan in the treatment of IgA nephropathy?
